Liraglutide, an injectable diabetes drug that US regulators approved last year for weight loss, helped obese people lose an average of 18 pounds (eight kilograms), a yearlong study said Wednesday. Most patients were able to keep the weight off for the duration of the 56-week study on the drug marketed as Saxenda by Novo Nordisk, according to the findings published in the New England Journal of Medicine.